Vista Pharmaceuticals Ltd does manufacturing and selling of Pharmaceutical, medical and veterinary preparations. The company also sells products to its related companies engaged in the manufacture of formulationsBusiness Overview: Company offers over-the-counter & prescription generic drug products consisting of tablets, capsules, and liquids covering various therapeutic categories. It formulates, registers,...
Mrs. Barkha Jain has resigned from her position as Company Secretary and Compliance Officer of Vista Pharmaceuticals Ltd to pursue an external career opportunity. This departure alters the key managerial personnel lineup for the firm, impacting corporate governance and compliance execution. Shareholders should monitor the transition and the subsequent appointment...
Vista Pharmaceuticals Limited announced it has completed its share dematerialization process for the quarter ended June 30, 2026. The company certified that all securities received for dematerialization were properly verified, mutilated, and cancelled. Crucially, the depository's name was updated as the registered owner in company records in a timely manner....
Vista Pharmaceuticals has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, issued by a Practicing Company Secretary, confirms the company's compliance with applicable regulatory provisions and guidelines during the review period. This update signifies sound corporate governance, with no reported deviations from...
Vista Pharmaceuticals has confirmed its routine compliance regarding the dematerialization of shares. The company ensured that all securities received for conversion to electronic form were meticulously cancelled after verification, and the depository's name was accurately substituted as the registered owner in company records. This crucial process ensures investor shareholdings are...
Vista Pharmaceuticals has announced a board meeting on February 13, 2026, to review and approve its financial results for the quarter and nine months ended December 31, 2025. During this meeting, the Board will also consider the Limited Review Report for the same period. This announcement is significant for investors,...
